Kornimate/medical-research-clean huggingface dataset:
meals to improve absorption of iron supplements

Conditions: Iron-deficiency; Iron Deficiency Anemia; Iron Deficiency Anemia Treatment

Summary: one of the targeted objectives of healthy people 2020 is to reduce iron deficiency among women of reproductive age (wra). consuming foods rich in iron and/or oral iron supplementation is typically recommended to improve iron status; however, global rates of iron deficiency remain high. thus, nutritional strategies to improve/maintain iron status are warranted. dietary iron is found in two different forms: heme and non-heme iron. non-heme iron is found in plant-based sources and is commonly used as a supplement and food fortificant. absorption of non-heme iron is low compared to heme iron, which is found in animal sources, such as beef. studies have also demonstrated that beef contains an unidentified factor that stimulates the absorption of non-heme iron. the primary objective of the proposed study is to determine the effects of incorporating daily meals containing beef or plant-based alternative with or without an iron supplement on indicators of iron status in iron-deficient wra.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) falls within the normal weight or overweight range (18.5-29.9 kg/m\^2) * low iron stores (serum ferritin \<25 μg/l) * willing to refrain from smoking and \>2 alcoholic drinks/week for the duration of the study period * willing to refrain from vitamin and mineral supplementation for the duration of the study exclusion criteria: * currently smoking or vaping * currently taking a medication that interferes with micronutrient metabolism * unwilling to refrain from vitamin and mineral supplementation for the duration of the study * restrictive diets (i.e., vegan or vegetarian diets) * metabolic or cardiovascular abnormalities (e.g., kidney disease, diabetes, cardiovascular disease, etc.) * history of any disease or abnormality of the gastrointestinal tract including, but not limited to, diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, crohn's disease, ulcerative colitis; or previous gastrointestinal surgery * blood donation within 4 months of beginning the study * abnormal blood clotting
volumetric study of the buttocks after flap augmentation in buttocks lifting

Conditions: Weight Loss

Summary: the development of bariatric surgery, its effectiveness and the reduction of complications are at the origin of massive weight loss, the corollary of which has been a clear increase in the demands of treatment of sequelae of weight loss.


Eligibility criteria:
inclusion criteria: * 12 months minimum delay with bariatric surgery * female, bmi\<30kg/m2 * age greater than or equal to 18 years * stable weight for more than 6 months * lack of volume in gluteal region * agree with clinical trial exclusion criteria: * patient under tutorship or curatorship * pregnancy or breastfeeding * hemoglobinemia\< 12g/dl * albuminemia\<3,5g/dl * active smoking more than 1 month before surgery

Keywords: plastic and reconstructive surgery gluteal ptosis platipygia
high dose steroids for dysphagia

Conditions: Dysphagia; Cervical Spine Disease

Summary: few existing data currently indicates that anti-inflammatory drugs could help diminish the local cervical inflammation tough to cause the dysphagia, hoarseness and dyspnea after an anterior surgical approach to the spine. this study aims to evaluate the effect of high dose of steroids on dysphagia after an anterior cervical spine procedure. patients subjected to a cervical spine surgery through an anterior approach will be randomized to a treatment group receiving 3 doses of iv dexamethasone (decadron) and a placebo group receiving saline. outcome will be measured with dysphagia scales, modified barium swallow and rhino-pharyngo-laryngoscopy, all done pre and post-operatively. secondary outcomes involve neurological condition, pain and fusion rate.


Eligibility criteria:
inclusion criteria: * anterior cervical spine surgery * elective surgery exclusion criteria: * takes steroids for any reason * pre-existing condition leading to dysphagia
multi-electrode pulmonary vein isolation versus single tip wide area catheter ablation for paroxysmal atrial fibrillation (paf)

Conditions: Atrial Fibrillation

Summary: the mystic_paf trial investigates the differences between treatment with a single-tip catheter against a multielectrode catheter in cardiac ablation procedures in patients with paroxysmal atrial fibrillation.


Eligibility criteria:
inclusion criteria: 1. history of symptomatic paroxysmal atrial fibrillation defined as: * self-terminating af with episodes lasting no more than seven consecutive days before spontaneous conversion back to sinus rhythm * documentation of one or more events with paf tracings by ecg, event recordings, pacemaker strips or monitor rhythm strips within the past year * af symptoms defined as the manifestation of any of the following: * palpitations * fatigue * exertional dyspnea * effort intolerance 2. age between 18 and 70 3. willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study exclusion criteria: 1. structural heart disease of clinical significance including: * previous cardiac surgery (excluding cabg) * symptoms of congestive heart failure including, but not limited to, nyha class iii or iv chf and/or documented ejection fraction \< 40% measured by acceptable cardiac testing * left atrial diameter of \> 50mm as measured in the parasternal long axis on transthoracic echocardiogram * stable/unstable angina or ongoing myocardial ischemia * myocardial infarction (mi) within three months of enrollment * aortic or mitral valve disease \> grade ii * congenital heart disease (not including asd or pfo without a right to left shunt) where the underlying abnormality increases the risk of an ablative procedure * prior asd or pfo closure with a device using a percutaneous approach * hypertrophic cardiomyopathy (lv wall thickness \> 1.5 cm) * pulmonary hypertension (mean or systolic pa pressure \>50mm hg on doppler echo 2. prior ablation for arrhythmias other than af within the past three months 3. prior left sided af ablation 4. enrollment in any other ongoing arrhythmia study protocol any ventricular tachyarrhythmias currently being treated where the arrhythmia or the management may interfere with this study

Keywords: ablation multi-electrode catheter single-tip catheter holter
new-onset atrial fibrillation complicating acute myocardial infarction in china

Conditions: New Onset Atrial Fibrillation; Acute Myocardial Infarction

Summary: to investigate the prognostic impacts of the atrial fibrillation burden (afb) in acute myocardial infarction (ami) patients who developed paroxysmal new-onset atrial fibrillation (noaf) during the index ami hospitalization.

in the present study, investigators retrospectively reviewed the medical records of all acute mi patients who were admitted to the coronary artery unit (ccu) of shanghai tenth people's hospital, kaifeng central hospital, and the first affiliated hospital of zhengzhou university between january 2014 and january 2022. all patients will routinely receive continuous electronic monitoring (cem) throughout their hospital stay to detect cardiac arrhythmias including the af events. of these, patients with ami without a history of af who developed a first documented af episode will be considered for inclusion. the afb is measured as a percentage (%) by dividing the total af duration by the total cem duration.

Eligibility criteria:
inclusion criteria: 1. patients hospitalized for ami including both stemi and nstemi between january 2014 and january 2022 at the ccu department of shanghai tenth people's hospital, kaifeng central hospital, and the first affiliated hospital of zhengzhou university. 2. patients who developed a first documented af (noaf) during the index ami hospitalization； 3. adult patients (\>18 years old). exclusion criteria: 1. patients with a medical history of pre-existing af; 2. patients with a medical history of rheumatic valvular disease; 3. patients with a medical history of sick sinus syndrome; 4. patients undergoing emergent coronary artery bypass surgery; 5. patients' medical records with serious deficiencies and cem data cannot be retrieved;

Keywords: myocardial infarction new-onset atrial fibrillation atrial fibrillation burden mortality
pain neuroscience education in old adults.

Conditions: Healthy

Summary: the primary objectives of this study are to: * evaluate the ability of the older adults to understand the biological processes underneath a pain experience. * evaluate their ability to modify their behaviors and beliefs about pain and health.

the purpose of this study is to test the effectivity of a single, group-based session of pain neuroscience education (pne) on old adults. participants will be 65 years or older, and they will be recruited from primary care medical clinics, public lectures, community centers and through the word of mouth. the intervention consist in one educational session of pain neuroscience education delivered by a physiotherapist. the study design is a single arm, crossover clinical trial, participants will be assessed in 3 different times (1 month before pne ,pre-pne, post-pne) for knowledge of pain neuroscience, pain attitudes, pain catastrophizing and pain-related fear of movement.

Eligibility criteria:
inclusion criteria: * subjects 65 years old or more. * able to speak and read in spanish. exclusion criteria: * cognitive impairment. global deterioration scale and functional assessment staging (gds-fast) will be used for the screening, excluding the subjects with a level 3 or above in the gds-fast scale.

Keywords: pain neuroscience education elderly pain education
therapeutic-educational physiotherapy on pain, physical-functionality and quality of life in women with endometriosis.

Conditions: Endometriosis; Chronic Pain; Women's Health

Summary: this is a randomized clinical trial that will be carried out in women with endometriosis divided into two groups: the experimental group (eg) that will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program, and the control group (cg) who will receive the pain education program. the participants will be evaluated at three moments: before starting the study (t1), after the 8-week treatment program (t2) and after another 8 weeks of follow-up in which they will be encouraged to continue with the treatment (t3). the initial assessment will include a medical and physiotherapy history, and at t1, t2 and t3 the following will be assessed: pain, abdominopelvic mobility, muscle status, functionality, sexual function, quality of life, stress and biomarkers of chronic inflammation.


Eligibility criteria:
inclusion criteria: * diagnosis of endometriosis made by imaging techniques (mri or ultrasound) or by surgery. * a period of 3 months or more since the last surgery if they have undergone surgery. * who are receiving hormone treatment and have their disease under control. * persistent pelvic pain for at least 3 months. * with pain and hypertonus in the pelvic musculature, myofascial syndrome, vestibulodynia or pudendal neuropathy. * consent to participate in the study * capable of carrying out the follow-up of the study until the final visit. * who have audiovisual resources and the internet at their disposal. exclusion criteria: * women in the menopausal phase * women undergoing fertility treatment or planning to undergo fertility treatment in the next 3 months. * pregnant women. * women undergoing physiotherapy treatment or who have undergone physiotherapy treatment in the last 3 months. * having suffered a fracture in the last 3 months in the lower limb that limits their functional capacity. * cognitive illness that prevents correct comprehension of the exercises. * musculoskeletal pathology or neuropathy in acute phase. * having suffered or suffering from a neoplastic disease. * untreated endometriosis * acquired genital abnormalities of the pelvis or pelvic floor. * women in a situation of litigation or economic compensation, or pending the granting of a degree of disability. * severe mental illness (schizophrenia, borderline personality disorder, etc.)

Keywords: endometriosis chronic pain physical therapy health education women
ivig for demyelination in diabetes mellitus

Conditions: Peripheral Neuropathy; Diabetes Mellitus; Chronic Inflammatory Demyelinating Polyneuropathy

Summary: the purpose of this study is to determine whether intravenous immunoglobulin (ivig) is an effective intervention for patients with diabetes, peripheral neuropathy, and demyelination on nerve conduction studies. all patients will receive both ivig and placebo for 3 months each, with a 3 month washout period in between.

there is a knowledge gap with regards to the appropriate method of detecting and treating chronic inflammatory demyelinating polyneuropathy (cidp), in patients with co-existent diabetes. in this pilot study the investigators plan to examine the overlap between diabetic polyneuropathy and cidp by treating patients with diabetes and demyelinating abnormalities using ivig. the investigators will enroll diabetes patients with a broad spectrum of demyelinating abnormalities. the proposed trial will be an explanatory, blinded, single-centre, superiority, randomized controlled cross-over trial. each patient will receive 3 months of 10% intravenous immunoglobulin and 3 months of placebo (0.9% sodium chloride in water) with a 3-month washout period. the primary outcome measure is the mean change in onls (overall neuropathy limitation scale), a measure of disability in polyneuropathy; however secondary outcome measures will consider impairments and quality of life.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. diabetes, as per american diabetes association criteria. 3. clinical evidence of polyneuropathy and ncs shows 2 separate motor nerves (median, ulnar, tibial, or peroneal) which meet criteria for demyelination, defined as follows: 1. conduction velocity \ 110% upper limit of normal (uln), or minimal f-wave latency \>110% uln 2. the changes are not exclusively due to median neuropathy at the wrist, ulnar neuropathy at the elbow, or peroneal neuropathy at the fibular head. 4. clinical suspicion of possible demyelinating polyneuropathy (cidp). exclusion criteria: 1. pregnant patients, or those of childbearing potential not using contraception. 2. patients \<18 years of age. 3. presence of an alternative etiology of peripheral neuropathy, such as: hereditary neuropathies (charcot marie-tooth disease); b-vitamin deficiency- or excess-related neuropathy; uremic neuropathy; neuropathy secondary to monoclonal gammopathy; history of cancer- or chemotherapy-related neuropathy; other toxin exposures; and alcoholic neuropathy. 4. contraindication to ivig, including: history of recurrent thrombosis, immunoglobulin a deficiency, or severe hypersensitivity reaction to ivig in past, renal failure, recurrent deep venous thrombosis, pulmonary embolus, stroke, or myocardial infarction. 5. presence of serious or unstable medical condition, which may preclude study completion or lead to inability to tolerate ivig. this may include active heart failure, uncontrolled hypertension, or severe anemia, among other conditions. 6. presence of concomitant neurological illness, which may confound evaluation. 7. fails or unable to provide informed consent.
car t-cells against cd30 (hsp-car30) for relapsed/ refractory hodgkin and t-cell lymphoma.

Conditions: Hodgkin Lymphoma, Adult; T Cell Lymphoma

Summary: hsp-car30 is a cell suspension of genetically modified t-cells to express a second generation (4-1bbz) chimeric antigen receptor (car) directed against cd30. this is a phase i/iia, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of hsp-car30 in patients with relapsed/refractory hodgkin lymphoma and relapsed/refractory t-cell lymphoma expressing cd30.


Eligibility criteria:
inclusion criteria: * classic hodgkin lymphoma: * relapsed patients after autologous hematopoietic stem cell transplantation who have already received brentuximab-vedotin and anti-pdl1 antibodies, or * primarily refractory patients who do not reach cr after rescue, including brentuximab-vedotin and anti-pdl1 antibodies. * anaplastic large t-cell lymphoma (alk+/alk-) and peripheral t-cell lymphoma (nos/angioimmunoblastic): * \>90% of tumor cells expressing cd30 determined by immunohistochemistry, and * relapsed patients after autologous hematopoietic stem cell transplantation, or * primarily refractory patients (after first line, including anthracycline) who do not achieve cr after rescue. * all patients must sign an informed consent before starting any procedure. * all patients must have measurable disease (detected by pet-ct) at the time of inclusion. * performance status: ecog 0-1 * fev1\> 39%; dlco and fvc\> 39% of nv. * no significant ventricular dysfunction: ef \>45%. * total bilirubin and transaminases \<3 times the maximum normal value, unless attributable to lymphoma. * creatinine \ 40 ml/min. exclusion criteria: * performance status: ecog 2-4 * prior allogeneic haematopoietic stem cell transplant. * active hepatitis b, c or hiv infection * active bacterial, fungal, or viral infection. * evidence of cns involvement by lymphoma.
use of an herbal preparation to prevent and dissolve kidney stones

Conditions: Cystinuria; Nephrolithiasis, Calcium Oxalate

Summary: we will investigate the safety and effectiveness of a mixture of 9 east indian herbs known as cystone regarding their ability to dissolve existing kidney stones and prevent formation of new ones. cystine and calcium stone formers will be recruited for a 59 week trial. the first phase of the study will be two 6 weeks periods during which each subject will receive cystone or placebo in random order (with a one-week wash out between 6 week treatment periods). the remaining 46 weeks, each subject will receive cystone. end points are changes in urinary chemistries and stone burden by computerized tomography (ct) scanning.

cystone will be used in proven cystine and calcium stone forming adults who are not pregnant. subjects must have a measurable stone by ct. the first phase is a double blind, randomized, placebo controlled cross-over of cystone and placebo for 6 weeks each separated by a 1 week washout. entry, 6 and 12 week 24 hour urine supersaturations or cystine, ph and sodium determinations will be collected. then all patients enter an open label phase of 46 weeks, ensuring a 52-week total exposure to cystone during the 59 week study. baseline and 1 year stone quantification ct scans will be performed. end points will be changes in urine chemistry/supersaturation and stone burden. stone burden was measured by ct, quantitatively for stone density and volume. all ct images were also reviewed in a blinded fashion by a radiologist to score each kidney as increased, no change or decreased stone burden. statistics and randomization: randomization was accomplished using a table provided by the department of statistics to the study coordinator who was blinded as to whether the patients received placebo or cystone®. biochemical and supersaturation results were analyzed via a matched pair analysis using the jmp software package (sas instituted, inc.); p values \< 0.05 were deemed significant.

Eligibility criteria:
inclusion criteria: * written informed consent in the cystine arm, all patients will have the diagnosis of cystinuria, made on the basis of a 24-hour urine cystine containing more than 1500 umol of cystine, or a stone compositional analysis of cystine * presence of an existing cystine stone in one or both kidneys in the calcium arm, all patients will have a history of a calcium stone as determined by laboratory analysis. * medically effective birth control if fertile female * able to comply with protocol exclusion criteria: * pregnant * subjects under age 18 years * obstructing stones * urinary tract infection that cannot be cleared with single course of antibiotic * subjects who decline to provide informed consent

Keywords: cystone uricare computerized tomography kidney calculi supersaturation nephrolithiasis quantitative ct
combined low frequency frontal and temporal rtms treatment in chronic tinnitus

Conditions: Tinnitus

Summary: transcranial magnetic stimulation is used to modulate the auditory neural pathways caused by hearing loss and leading to the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus.

tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. it is a frequent problem which can interfere significantly with the ability to lead a normal life. treatment is difficult. most available therapies focus on habituation rather than treating the cause. tinnitus is thought to be generated in the brain, as a result of functional reorganization of auditory neural pathways and tonotopic maps in the central auditory system, following damage to the peripheral auditory system. low-frequency rtms has been investigated for the treatment of hyperexcitability disorders such as auditory hallucinations and tinnitus. pilot data indicate that the beneficial effect of low-frequency rtms can be enhanced by low frequency rtms of the right dorsolateral prefrontal cortex (dlpfc). in the proposed study we investigate whether low frequency rtms of the dlpfc improves therapeutic efficacy of low-frequency rtms on tinnitus in a controlled trial.

Eligibility criteria:
inclusion criteria: * diagnosis of subjective chronic tinnitus * duration of tinnitus more than 3 months exclusion criteria: * objective tinnitus * treatable cause of the tinnitus * involvement in other treatments for tinnitus at the same time * clinically relevant psychiatric comorbidity * clinically relevant unstable internal or neurological comorbidity * history of or evidence of significant brain malformation or neoplasm, head injury * cerebral vascular events * neurodegenerative disorder affecting the brain or prior brain surgery; * metal objects in and around body that can not be removed * pregnancy * alcohol or drug abuse * prior treatment with tms

Keywords: tinnitus chronic subjective tinnitus transcranial magnetic stimulation sensation disorders hearing disorders
center m: digital health innovation pilot

Conditions: Perinatal Depression

Summary: center m is a digital health solution to perinatal depression (pd) which provides an alternative to mindfulness based cognitive therapy - perinatal depression (mbct-pd). center m shifts treatment to a telehealth model, reduces the number of sessions, and transitions home practice materials to a digital format. this study will include a clinical trial in which participants will be randomized to the center m treatment with smartphone app delivery of homework compared to treatment as usual (tau).


Eligibility criteria:
inclusion criteria: * currently pregnant * age 18-50 years * fluent in english * available and able to attend online group scheduled meetings exclusion criteria: * current or past enrollment in a mindfulness-based intervention group

Keywords: maternal mental health telehealth